These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27342131)

  • 1. The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.
    Monnier VM; Genuth S; Sell DR
    Glycoconj J; 2016 Aug; 33(4):569-79. PubMed ID: 27342131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes.
    Sell DR; Sun W; Gao X; Strauch C; Lachin JM; Cleary PA; Genuth S; ; Monnier VM
    Cardiovasc Diabetol; 2016 Feb; 15():30. PubMed ID: 26864236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.
    Monnier VM; Sun W; Gao X; Sell DR; Cleary PA; Lachin JM; Genuth S;
    Cardiovasc Diabetol; 2015 Sep; 14():118. PubMed ID: 26341632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes.
    Genuth S; Sun W; Cleary P; Gao X; Sell DR; Lachin J; ; Monnier VM
    Diabetes; 2015 Jan; 64(1):266-78. PubMed ID: 25187362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes.
    Monnier VM; Sell DR; Strauch C; Sun W; Lachin JM; Cleary PA; Genuth S;
    J Diabetes Complications; 2013; 27(2):141-9. PubMed ID: 23153673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.
    Genuth S; Sun W; Cleary P; Sell DR; Dahms W; Malone J; Sivitz W; Monnier VM;
    Diabetes; 2005 Nov; 54(11):3103-11. PubMed ID: 16249432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin collagen pentosidine and fluorescence in diabetes were predictors of retinopathy progression and creatininemia increase already 6years after punch-biopsy.
    Sternberg M; M'bemba J; Urios P; Borsos AM; Selam JL; Peyroux J; Slama G
    Clin Biochem; 2016 Feb; 49(3):225-31. PubMed ID: 26506116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intima-media thickness at different arterial segments in pediatric type 1 diabetes patients and its relationship with advanced glycation end products.
    Lilje C; Cronan JC; Schwartzenburg EJ; Owers EM; Clesi P; Gomez R; Stender S; Hempe J; Chalew SA; Cardinale JP
    Pediatr Diabetes; 2018 May; 19(3):450-456. PubMed ID: 28664608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucosepane and oxidative markers in skin collagen correlate with intima media thickness and arterial stiffness in long-term type 1 diabetes.
    Sveen KA; Dahl-Jørgensen K; Stensaeth KH; Angel K; Seljeflot I; Sell DR; Monnier VM; Hanssen KF
    J Diabetes Complications; 2015 Apr; 29(3):407-12. PubMed ID: 25600701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermal microvessel density and maturity is closely associated with atherogenic dyslipidemia and accumulation of advanced glycation end products in adult patients with type 1 diabetes.
    Adamska A; Araszkiewicz A; Pilacinski S; Gandecka A; Grzelka A; Kowalska K; Malinska A; Nowicki M; Zozulinska-Ziolkiewicz D
    Microvasc Res; 2019 Jan; 121():46-51. PubMed ID: 30312628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes.
    Fokkens BT; Smit AJ
    Glycoconj J; 2016 Aug; 33(4):527-35. PubMed ID: 27287226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collagen methionine sulfoxide and glucuronidine/LW-1 are markers of coronary artery disease in long-term survivors with type 1 diabetes. The Dialong study.
    Holte KB; Svanteson M; Hanssen KF; Sveen KA; Seljeflot I; Solheim S; Sell DR; Monnier VM; Berg TJ
    PLoS One; 2020; 15(5):e0233174. PubMed ID: 32401813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications.
    Monnier VM; Sun W; Sell DR; Fan X; Nemet I; Genuth S
    Clin Chem Lab Med; 2014 Jan; 52(1):21-32. PubMed ID: 23787467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review.
    Bos DC; de Ranitz-Greven WL; de Valk HW
    Diabetes Technol Ther; 2011 Jul; 13(7):773-9. PubMed ID: 21510765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial.
    Monnier VM; Bautista O; Kenny D; Sell DR; Fogarty J; Dahms W; Cleary PA; Lachin J; Genuth S
    Diabetes; 1999 Apr; 48(4):870-80. PubMed ID: 10102706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study.
    Araszkiewicz A; Naskret D; Zozulinska-Ziolkiewicz D; Pilacinski S; Uruska A; Grzelka A; Wegner M; Wierusz-Wysocka B
    Microvasc Res; 2015 Mar; 98():62-7. PubMed ID: 25582078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study.
    Saremi A; Howell S; Schwenke DC; Bahn G; Beisswenger PJ; Reaven PD;
    Diabetes Care; 2017 Apr; 40(4):591-598. PubMed ID: 28148544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study.
    Noordzij MJ; Mulder DJ; Oomen PH; Brouwer T; Jager J; Castro Cabezas M; Lefrandt JD; Smit AJ
    Diabet Med; 2012 Dec; 29(12):1556-61. PubMed ID: 22937960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus.
    Lyons TJ; Bailie KE; Dyer DG; Dunn JA; Baynes JW
    J Clin Invest; 1991 Jun; 87(6):1910-5. PubMed ID: 1904067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between cardiac tissue glycation and skin autofluorescence in patients with coronary artery disease.
    Hofmann B; Jacobs K; Navarrete Santos A; Wienke A; Silber RE; Simm A
    Diabetes Metab; 2015 Nov; 41(5):410-5. PubMed ID: 25553578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.